Risk Factor (RF) | HR | 95% CI |
Comorbidities, ≥2 | 1.19 | 1.04 - 1.36 |
ECOG, ≥2 | 1.40 | 0.99 - 2.14 |
Signet Ring Cells, >50% | 1.37 | 1.07 - 1.72 |
Her2 Treated with Trastuzumab | 0.71 | 0.50 - 0.96 |
Metastatic Sites, ≥2 | 1.26 | 1.08 - 1.63 |
CEA, ≥20 | 1.32 | 1.23 - 1.69 |
Bone Metastases | 1.99 | 1.37 - 2.89 |
Ascitis | 1.67 | 1.26 - 2.21 |